Alteogen Moves Toward the Main Board…Shareholders Approve “KOSPI Transfer Listing”
Alteogen, the No. 1 company on KOSDAQ by market capitalization, is set to move to Korea’s main bourse,…
Alteogen
8 개의 기사가 있습니다.
Alteogen Set to Accelerate Licensing After FDA Clears Keytruda SC
The U.S. Food and Drug Administration (FDA) has approved Merck’s (MSD) subcutaneous (SC) formulation of its blockbuster immunotherapy…
Alteogen’s Eylea Biosimilar Clears EU Hurdle
Alteogen has cleared a major regulatory hurdle in its bid to enter the European biosimilar market. The Korean…
Alteogen May Qualify for KOSPI…Management Holds the Key
Will Alteogen, a South Korean biopharmaceutical company, make the leap from KOSDAQ to KOSPI? The question has gained…
PTAB Grants Merck Review of Halozyme Patent Claims, Boosting Alteogen’s Milestone Prospects
The U.S. Patent Trial and Appeal Board (PTAB) has instituted a post-grant review of a key Halozyme patent,…
Alteogen Receives USD 20 Million Upfront Payment from Daiichi Sankyo
Alteogen announced that it has received an upfront payment of USD 20 million (approximately KRW 28 billion) from…
Global Pharma Companies Lining Up at Alteogen's Door – Why?
"By the 2030s, I envision Alteogen joining the ranks of companies with annual revenue in the trillions of…
Alteogen Signs USD 280 Million Licensing Agreement with Daiichi Sankyo
Alteogen is advancing in the development of the world’s first subcutaneous (SC) injection for antibody-drug conjugates (ADCs). On…